The complement component C5a induces the expression of plasminogen activator inhibitor-1 in human macrophages via NF-κB activation

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 8, 2006, Pages 1790-1797

  Kastl, S P ^a   Speidl, W S ^a   Kaun, C ^a   Rega, G ^a,b   Assadian, A ^c   Weiss, T W ^a   Valent, P ^a   Hagmueller, G W ^c   Maurer, G ^a   Huber, K ^b   Wojta, Johann ^a,d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Wilhelminenhospital   (Austria)

^c 1st Department of General and Vascular Surgery   (Austria)

^d Ludwig Boltzmann Cluster for Cardiovascular Research   (Austria)

Author keywords

Complement; Inflammation; Monocytes macrophages; Plasminogen activator inhibitor 1

Indexed keywords

COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PERTUSSIS TOXIN; PLASMINOGEN ACTIVATOR INHIBITOR; TIRON; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANALYSIS OF VARIANCE; ARTICLE; ATHEROSCLEROSIS; CELL CULTURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INCUBATION TIME; MACROPHAGE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY BURST; RNA PURIFICATION; THROMBOGENESIS; UPREGULATION;

CELLS, CULTURED; COMPLEMENT C3A; COMPLEMENT C5A; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MACROPHAGES; MEMBRANE PROTEINS; MONOCYTES; NF-KAPPA B; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, COMPLEMENT; RECOMBINANT PROTEINS; RNA, MESSENGER; TIME FACTORS; UP-REGULATION;

EID: 33746585656     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.02046.x     Document Type: Article

References (42)

1. Braunwald E. Shattuck lecture - cardiovascular medicine at the turn of the millennium: Triumphs, concerns, and opportunities. N Engl J Med 1997; 337: 1360-9.
2. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
3. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
4. Morgan BP, Harris CL. Complement therapeutics; history and current progress. Mol Immunol 2003; 40: 159-70.
5. Niculescu F, Rus H. Complement activation and atherosclerosis. Mol Immunol 1999; 36: 949-55.
6. Kostner KM. Activation of the complement system: A crucial link between inflammation and atherosclerosis ? Eur J Clin Invest 2004; 34: 800-2.
7. Torzewski M, Klouche M, Hock J, Messner M, Dorweiler B, Torzewski J, Gabbert HE, Bhakdi S. Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler Thromb Vasc Biol 1998; 18: 369-78.
8. Speidl WS, Exner M, Amighi J, Kastl SP, Zorn G, Maurer G, Wagner O, Huber K, Minar E, Wojta J, Schillinger M. Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. Eur Heart J 2005; 26: 2294-9.
9. Schulman ES, Post TJ, Henson PM, Giclas PC. Differential effects of the complement peptides, C5a and C5a des Arg on human basophil and lung mast cell histamine release. J Clin Invest 1988; 81: 918-23.
10. Nataf S, Davoust N, Ames RS, Barnum SR. Human T cells express the C5a receptor and are chemoattracted to C5a. J Immunol 1999; 162: 4018-23.
11. Murakami Y, Imamichi T, Nagasawa S. Characterization of C3a anaphylatoxin receptor on guinea-pig macrophages. Immunology 1993; 79: 633-8.
12. Takabayashi T, Vannier E, Clark BD, Margolis NH, Dinarello CA, Burke JF, Gelfand JA. A new biologic role for C3a and C3a desArg: Regulation of TNF-alpha and IL-1 beta synthesis. J Immunol 1996; 156: 3455-60.
13. Takabayashi T, Vannier E, Burke JF, Tompkins RG, Gelfand JA, Clark BD. Both C3a and C3a(desArg) regulate interleukin-6 synthesis in human peripheral blood mononuclear cells. J Infect Dis 1998; 177: 1622-8.
14. Okusawa S, Yancey KB, van der Meer JW, Endres S, Lonnemann G, Hefter K, Frank MM, Burke JF, Dinarello CA, Gelfand JA. C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1 beta and interleukin 1 alpha. J Exp Med 1988; 168: 443-8.
15. Foreman KE, Vaporciyan AA, Bonish BK, Jones ML, Johnson KJ, Glovsky MM, Eddy SM, Ward PA. C5a-induced expression of P-selectin in endothelial cells. J Clin Invest 1994; 94: 1147-55.
16. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342: 1792-801.
17. Lupu F, Heim DA, Bachmann F, Hurni M, Kakkar VV, Kruithof EK. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1995; 15: 1444-55.
18. Tipping PG, Davenport P, Gallicchio M, Filonzi EL, Apostolopoulos J, Wojta J. Atheromatous plaque macrophages produce plasminogen activator inhibitor type-1 and stimulate its production by endothelial cells and vascular smooth muscle cells. Am J Pathol 1993; 143: 875-85.
19. Colli S, Lalli M, Rise P, Mussoni L, Eligini S, Galli C, Tremoli E. Increased thrombogenic potential of human monocyte-derived macrophages spontaneously transformed into foam cells. Thromb Haemost 1999; 81: 576-81.
20. Wojta J, Kaun C, Zorn G, Ghannadan M, Hauswirth AW, Sperr WR, Fritsch G, Printz D, Binder BR, Schatzl G, Zwirner J, Maurer G, Huber K, Valent P. C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils. Blood 2002; 100: 517-23.
21. Zwirner J, Gotze O, Moser A, Sieber A, Begemann G, Kapp A, Elsner J, Werfel T. Blood- and skin-derived monocytes/macrophages respond to C3a but not to C3a(desArg) with a transient release of calcium via a pertussis toxin-sensitive signal transduction pathway. Eur J Immunol 1997; 27: 2317-22.
22. Speidl WS, Toller WG, Kaun C, Weiss TW, Pfaffenberger S, Kastl SP, Furnkranz A, Maurer G, Huber K, Metzler H, Wojta J. Catecholamines potentiate LPS-induced expression of MMP-1 and MMP-9 in human monocytes and in the human monocytic cell line U937: Possible implications for peri-operative plaque instability. FASEB J 2004; 18: 603-5.
23. Steiner S, Seidinger D, Huber K, Kaun C, Minar E, Kopp CW. Effect of glycoprotein IIb/IIIa antagonist abciximab on monocyte-platelet aggregates and tissue factor expression. Arterioscler Thromb Vasc Biol 2003; 23: 1697-702.
24. Peiretti F, Bernot D, Lopez S, Bonardo B, Deprez-Beauclair P, Juhan-Vague I, Nalbone G. Modulation of PAI-1 and proMMP-9 syntheses by soluble TNFalpha and its receptors during differentiation of the human monocytic HL-60 cell line. J Cell Physiol 2003; 196: 346-53.
25. 2 generation by alveolar macrophages. Free Radic Biol Med 2002; 32: 1304-13.
26. Hsu MH, Wang M, Browning DD, Mukaida N, Ye RD. NF-kappaB activation is required for C5a-induced interleukin-8 gene expression in mononuclear cells. Blood 1999; 93: 3241-9.
27. Hou B, Eren M, Painter CA, Covington JW, Dixon JD, Schoenhard JA, Vaughan DE. Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site. J Biol Chem 2004; 279: 18127-36.
28. Tobe M, Isobe Y, Tomizawa H, Nagasaki T, Takahashi H, Fukazawa T, Hayashi H. Discovery of quinazolines as a novel structural class of potent inhibitors of NF-kappa B activation. Bioorg Med Chem 2003; 11: 383-91.
29. Laine P, Pentikainen MO, Wurzner R, Penttila A, Paavonen T, Meri S, Kovanen PT. Evidence for complement activation in ruptured coronary plaques in acute myocardial infarction. Am J Cardiol 2002; 90: 404-8.
30. Torzewski J, Bowyer DE, Waltenberger J, Fitzsimmons C. Processes in atherogenesis: Complement activation. Atherosclerosis 1997; 132: 131-8.
31. Steins MB, Padro T, Schwaenen C, Ruiz S, Mesters RM, Berdel WE, Kienast J. Overexpression of urokinase receptor and cell surface urokinase-type plasminogen activator in the human vessel wall with different types of atherosclerotic lesions. Blood Coagul Fibrinolysis 2004; 15: 383-91.
32. Nilsson G, Johnell M, Hammer CH, Tiffany HL, Nilsson K, Metcalfe DD, Siegbahn A, Murphy PM. C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. J Immunol 1996; 157: 1693-8.
33. Peiretti F, Lopez S, Deprez-Beauclair P, Bonardo B, Juhan-Vague I, Nalbone G. Inhibition of p70(S6) kinase during transforming growth factor-beta 1/vitamin D(3)-induced monocyte differentiation of HL-60 cells allows tumor necrosis factor-alpha to stimulate plasminogen activator inhibitor-1 synthesis. J Biol Chem 2001; 276: 32214-9.
34. Shatos MA, Doherty JM, Orfeo T, Hoak JC, Collen D, Stump DC. Modulation of the fibrinolytic response of cultured human vascular endothelium by extracellularly generated oxygen radicals. J Biol Chem 1992; 267: 597-601.
35. Kukreja P, Abdel-Mageed AB, Mondal D, Liu K, Agrawal KC. Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-kappaB activation. Cancer Res 2005; 65: 9891-8.
36. Yasojima K, Schwab C, McGeer EG, McGeer PL. Complement components, but not complement inhibitors, are upregulated in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001; 21: 1214-9.
37. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003; 170: 191-203.
38. Hamilton JA, Whitty GA, Stanton H, Wojta J, Gallichio M, McGrath K, Ianches G. Macrophage colony-stimulating factor and granulocyte-macrophage colony-stimulating factor stimulate the synthesis of plasminogen-activator inhibitors by human monocytes. Blood 1993; 82: 3616-21.
39. Hamilton JA, Whitty GA, Wojta J, Gallichio M, McGrath K, Ianches G. Regulation of plasminogen activator inhibitor-1 levels in human monocytes. Cell Immunol 1993; 152: 7-17.
40. Horton MR, Olman MA, Bao C, White KE, Choi AM, Chin BY, Noble PW, Lowenstein CJ. Regulation of plasminogen activator inhibitor-1 and urokinase by hyaluronan fragments in mouse macrophages. Am J Physiol Lung Cell Mol Physiol 2000; 279: L707-15.
41. Muhlfelder TW, Niemetz J, Kreutzer D, Beebe D, Ward PA, Rosenfeld SI. C5 chemotactic fragment induces leukocyte production of tissue factor activity: A link between complement and coagulation. J Clin Invest 1979; 63: 147-50.
42. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987; ii: 3-9.